These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 8334422

  • 1. Sensitivity of human CFU-GM to mafosfamide: analysis of the factors affecting individual variations.
    Domenech J, Desbois I, Linassier C, Gihana E, Chenault S, Brémond JL, Colombat P, Lamagnère JP, Binet C.
    Bone Marrow Transplant; 1993 Jun; 11(6):425-31. PubMed ID: 8334422
    [Abstract] [Full Text] [Related]

  • 2. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC.
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [Abstract] [Full Text] [Related]

  • 3. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
    Douay L, Giarratana MC, Labopin M, Bardinet D, Bouchet S, Gorin NC.
    Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
    [Abstract] [Full Text] [Related]

  • 4. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
    Martin H, Bruecher J, Claudé R, Hoelzer D.
    Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
    [Abstract] [Full Text] [Related]

  • 5. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
    Giarratana MC, Gorin NC, Douay L.
    Nouv Rev Fr Hematol (1978); 1995 Nov; 37(2):125-30. PubMed ID: 7644349
    [Abstract] [Full Text] [Related]

  • 6. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 7. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L, Laporte JP, Mary JY, Lopez M, Lemonnier MP, Stachowiak J, Benitez O, Deloux J, Najman A, Salmon C.
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [Abstract] [Full Text] [Related]

  • 8. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
    Carlo-Stella C, Mangoni L, Almici C, Cottafavi L, Meloni G, Mandelli F, Rizzoli V.
    Blood; 1992 Nov 01; 80(9):2412-8. PubMed ID: 1421413
    [Abstract] [Full Text] [Related]

  • 9. Successful blood stem cell collection and transplant in children weighing less than 25 kg.
    Deméocq F, Kanold J, Chassagne J, Bezou MJ, Lutz P, deLumley L, Philip I, Vannier JP, Margueritte G, Lamagnére JP.
    Bone Marrow Transplant; 1994 Jan 01; 13(1):43-50. PubMed ID: 7912601
    [Abstract] [Full Text] [Related]

  • 10. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
    Douay L, Mary JY, Giarratana MC, Najman A, Gorin NC.
    Exp Hematol; 1989 Jun 01; 17(5):429-32. PubMed ID: 2653856
    [Abstract] [Full Text] [Related]

  • 11. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
    Gidáli J, Fehér I.
    Bone Marrow Transplant; 1992 Dec 01; 10(6):479-83. PubMed ID: 1490197
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT, Krog C, Stockschläder M, Schleimer B, Zeller W, Krüger W, Erttmann R, Zander AR.
    Anticancer Res; 1997 Dec 01; 17(1B):589-99. PubMed ID: 9066585
    [Abstract] [Full Text] [Related]

  • 13. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S.
    Exp Hematol; 1995 Dec 01; 23(14):1520-6. PubMed ID: 8542941
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M, Couture F, Kovacs M, Saragosa R, McCrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L, Keating A.
    Exp Hematol; 1993 Mar 01; 21(3):405-410. PubMed ID: 8440338
    [Abstract] [Full Text] [Related]

  • 15. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A, Koristek Z, Vinklarkova J, Pavlik T, Sticha M, Navratil M, Kral Z, Vasova I, Mayer J.
    Exp Hematol; 2009 Nov 01; 37(11):1266-73. PubMed ID: 19654036
    [Abstract] [Full Text] [Related]

  • 16. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution.
    Gorin NC, Labopin M, Laporte JP, Douay L, Lopez M, Lesage S, Fouillard L, Isnard F, Jouet JP, Bellal N, Perot C, Van Den Akker J, Bauters F, Najman A.
    Exp Hematol; 1999 Dec 01; 27(12):1822-30. PubMed ID: 10641600
    [Abstract] [Full Text] [Related]

  • 17. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M, Sureda A, Martino R, Madoz P, García J, Brunet S.
    Haematologica; 1998 May 01; 83(5):428-31. PubMed ID: 9658727
    [Abstract] [Full Text] [Related]

  • 18. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience.
    Laporte JP, Douay L, Lopez M, Labopin M, Jouet JP, Lesage S, Stachowiak J, Fouillard L, Isnard F, Noel-Walter MP.
    Blood; 1994 Dec 01; 84(11):3810-8. PubMed ID: 7949137
    [Abstract] [Full Text] [Related]

  • 19. Activated lymphocytes in the marrow cell suspension decrease the mafosfamide-induced CFU-GM cytotoxicity.
    Woźny T, Sawiński K, Kozłowska-Skrzypczak M, Hansz J.
    Acta Haematol Pol; 1995 Dec 01; 26(4):367-75. PubMed ID: 8571738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.